Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RG2417
Uridine · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| RG2417 | EXPERIMENTAL | Oral RG2417 taken twice daily for 8 weeks |
| Placebo | PLACEBO_COMPARATOR | Oral placebo taken twice daily for 8 weeks |
| Name | Type | Description |
|---|---|---|
| RG2417 | DRUG | 1g bid dose escalates to 2g bid for weeks 2-8. |
| Placebo | DRUG | Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets. |
| Uridine | DRUG | - |
Inclusion Criteria: * Bipolar I Disorder, most recent episode depressed * History of 2 or more manic or mixed episodes, at least one of which required pharmacologic treatment for manic symptoms Exclusion Criteria: * Current manic, hypomanic or mixed episode * Rapid cycling bipolar disorder (4 or ...
Uridine is an investigational small molecule being studied for the treatment of Bipolar Depression. It is being developed by Repligen Corporation (NASDAQ: RGEN). The drug is currently in Phase 2 clinical development, meaning it is still being tested in clinical trials and is not yet approved for use.
The specific molecular target of Uridine has not been disclosed. It is a small molecule being investigated for its potential therapeutic effects in Bipolar Depression. The drug is being developed by Repligen Corporation (NASDAQ: RGEN) and is currently in Phase 2 clinical trials.
Uridine is being developed by Repligen Corporation, a biopharmaceutical company traded on NASDAQ under the ticker symbol RGEN. The company is conducting clinical research to evaluate the drug as a potential treatment for Bipolar Depression. Uridine is currently in Phase 2 clinical development.
Uridine is in Phase 2 clinical development for the treatment of Bipolar Depression. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in a completed Phase 2 clinical trial to assess its safety and efficacy in patients with Bipolar I Depression.
Uridine has one completed Phase 2 clinical trial registered under NCT00322764, titled "Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression." The trial enrolled 80 participants in the United States and was a randomized, double-blind study. The drug is being developed by Repligen Corporation (NASDAQ: RGEN).
Yes, Uridine is also known as RG2417. The Phase 2 clinical trial NCT00322764, which evaluated the drug for Bipolar I Depression, used the name RG2417 in its title. Repligen Corporation (NASDAQ: RGEN) is the developer of this investigational small molecule.